Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cisplatin + Pembrolizumab + Pemetrexed & Pleural mesothelioma, on September 17, 2024, the Food and Drug Administration approved Carboplatin/Cisplatin + Pembrolizumab + Pemetrexed as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma
Source: SITC Oncology News Burst 09/19/2024
The EMA approved Carboplatin/Cisplatin + Pembrolizumab + Pemetrexed as first-line treatment of unresectable …